Highlights from Q1 2022 Webinar

It was great to see over 100 drug hunters at our first drug discovery webinar! You can find the video and slides at the bottom of this page. The scope of this talk grew to be a bit massive as we were planning it, so we decided to split it into two parts. This first part covered:

  • Interesting tidbits from 2022 Q1’s drug approvals
  • Cool facets from some of the recent Molecules of the Month
  • Highlights from recent conference disclosures

Part II will cover:

  • Emerging startups, growing drug discovery companies, and IPOs
  • Clinical readouts, positive and negative
  • Big deals and major regulatory actions

You can sign up for our Drug Hunter web series here:

We’re excited about the line-up of speakers we’ll have coming soon for you! If you have someone you’d love to hear from, let us know, and we we’ll work on inviting them over.

Preview of Part II

A preview of what’s coming in part II

Highlights from Q1 2022 Recording

In case you missed Part I, you can check out the video here on our new YouTube channel:

Highlights from Q1 2022 Slides

… and you can view the slides here:

RECENT ARTICLES

DRUG DISCOVERY RESOURCES

JOIN SUBSCRIBERS from

  • Johnson & Johnson
  • Roche
  • Pfizer
  • Novartis
  • Bayer
  • Merck
  • Sanofi
  • GlaxoSmithKline
  • AbbVie
  • Eli Lilly
  • Boehringer Ingelheim
  • Amgen
  • Bristol-Myers Squibb
  • Gilead
  • AstraZeneca
  • Teva
  • Novo Nordisk
  • Merck KGaA
  • Takeda
  • Celgene (BMS)
  • Biogen
  • Astellas
  • Daiichi Sankyo
  • Regeneron
  • UCB
  • Eisai
  • Servier
  • Kyowa Kirin
  • Shionogi
  • Vertex
  • Lundbeck
  • Taisho
  • Ono
  • Seagen
  • Incyte
  • LEO Pharma
  • Janssen
  • Galapagos
  • Idorsia
  • Astex
  • Arvinas
  • Kymera
  • Relay
  • Schrodinger
  • Mirati
  • Revolution
  • Nimbus
  • Plexxikon
  • Forma
  • Arcus
  • RA Capital
  • ARCH Venture Partners
  • MPM Capital
  • Orbimed
  • The Column Group
  • 5AM Ventures
  • Versant Ventures
  • Deerfield
  • Goldman Sachs
  • Citi
  • Piper Sandler
  • Softbank
  • …and hundreds of others